Skip to main content
. 2013 Jun 4;21(9):1749–1757. doi: 10.1038/mt.2013.112

Figure 5.

Figure 5

Sunitinib enhances the oncolytic efficacy VSV against 4T1 breast tumors in immunocompetent mice. Mouse mammary tumor cells 4T1 were implanted subcutaneously in BALB/c mice. Daily orally sunitinib treatments began on day 12 postimplantation (dashed line). Intratumoral injection with VSV was done on day 14 (arrows). Tumor sizes were measured using a digital caliper and data were analyzed in GraphPadPrizm. Su, sunitinib; VSV, vesicular stomatitis virus.